Litcius/Paper detail

Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy

Naïm Bouazza, Saı̈k Urien, Frantz Foissac, Laure Choupeaux, Gabrielle Lui, Léo Froelicher Bournaud, Steeve Rouillon, Yi Zheng, Emmanuelle Bardin, Nathalie Stremler, Katia Bessaci, Tiphaine Bihouée, Emmanuelle Coirier-Duet, Christophe Marguet, Eric Deneuville, Muriel Laurans, Philippe Reix, M. Gérardin, Marie Mittaine, Ralph Epaud, C. Thumerelle, Laurence Weiss, Romain Berthaud, Michaëla Semeraro, Jean‐Marc Tréluyer, Sihem Benaboud, Isabelle Sermet‐Gaudelus

2024Clinical Pharmacokinetics10 citationsDOI

Topics & Concepts

IvacaftorCystic fibrosisMedicinePharmacokineticsPopulationPharmacologyInternal medicineCystic fibrosis transmembrane conductance regulatorEnvironmental healthCystic Fibrosis Research AdvancesAsthma and respiratory diseasesSinusitis and nasal conditions
Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy | Litcius